Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...
Morning Overview on MSN
NASA outlines the 5 biggest dangers of human spaceflight
Human spaceflight is built on a simple paradox: the farther people travel from Earth, the more fragile their bodies and ...
As we scroll through feeds that feel more like mirrors than marketplaces, are we hunting for deals, or are the deals are ...
As of the November 30, 2025 data cutoff, two patients with non-Hodgkin's lymphoma had completed multiple GT801 administrations without lymphodepleting chemotherapy, demonstrating the feasibility of ...
How SA leaders are reshaping enterprise CX in the age of AIIssued by ConnectJohannesburg, 10 Dec 2025 Greg Jarvis, Head of Customer Success at Connect SA. South Africa’s customer experience (CX) ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
The answer, according to new research from the data and AI platform company, is sobering. Even the best-performing AI agents achieve less than 45% accuracy on tasks that mirror real enterprise ...
Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...
Non-invasive recordings using brain electrophysiology provide credible insights into decline in neuronal functioning with age. New approaches are required to translate these results into compelling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback